DNA

Co-Diagnostics, Inc. to Present at Sidoti Virtual Investor Conference

Monday, September 20, 2021 - 10:03pm

SALT LAKE CITY, Sept. 20, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX) a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Dwight Egan, CEO, Brian Brown, CFO, and Andrew Benson, Head of Investor Relations, will present and host one-on-one meetings with investors at the Sidoti Fall Virtual Investor Conference.

Key Points: 
  • SALT LAKE CITY, Sept. 20, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX) a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Dwight Egan, CEO, Brian Brown, CFO, and Andrew Benson, Head of Investor Relations, will present and host one-on-one meetings with investors at the Sidoti Fall Virtual Investor Conference.
  • The presentation will begin at 3:15 p.m. EDT on Thursday, September 23, 2021, and can be accessed on the Events and Webcasts section of the Co-Diagnostics website.
  • Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology.
  • The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA).

InsideTracker Partners with Shalane Flanagan on World Marathon Majors Feat, Project Eclipse

Monday, September 20, 2021 - 5:01pm

CAMBRIDGE, Mass., Sept. 20, 2021 /PRNewswire/ -- Shalane Falanagan today announced Project Eclipse, a mission to run all six World Marathon Majors, starting September 26 in Berlin and concluding November 7 in New York City, at the site of her 2017 championship win.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 20, 2021 /PRNewswire/ -- Shalane Falanagan today announced Project Eclipse, a mission to run all six World Marathon Majors, starting September 26 in Berlin and concluding November 7 in New York City, at the site of her 2017 championship win.
  • This personalized feedback will help to inform her strategy based on real-time nutrition, inflammation and recovery markers.
  • Flanagan is one of the most decorated and celebrated American runners in history.
  • "InsideTracker is honored to be an essential part of Shalane's support team for Project Eclipse," said Mariah Bridges, director of demand generation, InsideTracker.

ciValue launches Retail Media Intelligence solution

Monday, September 20, 2021 - 4:00pm

TEL AVIV, Israel and ATLANTA, Sept. 20, 2021 /PRNewswire/ --ciValue today announced the launch of its Retail Media Intelligence solution for retailers looking to maximize the monetization of their media assets across physical and digital channels.

Key Points: 
  • TEL AVIV, Israel and ATLANTA, Sept. 20, 2021 /PRNewswire/ --ciValue today announced the launch of its Retail Media Intelligence solution for retailers looking to maximize the monetization of their media assets across physical and digital channels.
  • ciValue's Retail Media Intelligence solution enables retailers and their suppliers or other business partners, to plan, predict, and optimize their media investments with dedicated mechanisms for: insights sharing, proactive audience building, audiences onboarding to owned or external media, and impact analysis across all channels.
  • ciValue's Retail Media Intelligence solution fits into the retailer's existing retail media ecosystem and can be deployed within 8 weeks, transforming the current business model with a self-serve platform.
  • ciValue's Retail Media Intelligence solution enhances retail media networks initiatives with a smart layer for campaign, trade and digital managers to derive their decisions from data-driven insights, cut their time to plan and launch highly effective campaigns, and measure their sales performance across all channels.

ciValue launches Retail Media Intelligence solution

Monday, September 20, 2021 - 4:00pm

TEL AVIV, Israel and ATLANTA, Sept. 20, 2021 /PRNewswire/ -- ciValue today announced the launch of its Retail Media Intelligence solution for retailers looking to maximize the monetization of their media assets across physical and digital channels. ciValue's Retail Media Intelligence solution enables retailers and their suppliers or other business partners, to plan, predict, and optimize their media investments with dedicated mechanisms for: insights sharing, proactive audience building, audiences onboarding to owned or external media, and impact analysis across all channels. ciValue's Retail Media Intelligence solution fits into the retailer's existing retail media ecosystem and can be deployed within 8 weeks, transforming the current business model with a self-serve platform.

Key Points: 
  • TEL AVIV, Israel and ATLANTA, Sept. 20, 2021 /PRNewswire/ --ciValue today announced the launch of its Retail Media Intelligence solution for retailers looking to maximize the monetization of their media assets across physical and digital channels.
  • ciValue's Retail Media Intelligence solution enables retailers and their suppliers or other business partners, to plan, predict, and optimize their media investments with dedicated mechanisms for: insights sharing, proactive audience building, audiences onboarding to owned or external media, and impact analysis across all channels.
  • ciValue's Retail Media Intelligence solution fits into the retailer's existing retail media ecosystem and can be deployed within 8 weeks, transforming the current business model with a self-serve platform.
  • ciValue's Retail Media Intelligence solution enhances retail media networks initiatives with a smart layer for campaign, trade and digital managers to derive their decisions from data-driven insights, cut their time to plan and launch highly effective campaigns, and measure their sales performance across all channels.

MUSC and Helix launch In Our DNA SC, first-of-its-kind population genomics program to drive preventive, precision health care for South Carolinians

Monday, September 20, 2021 - 3:00pm

The large-scale program is designed to improve health care outcomes by integrating genetic insights into clinical care and research.

Key Points: 
  • The large-scale program is designed to improve health care outcomes by integrating genetic insights into clinical care and research.
  • Medical University of South Carolina and Helix to develop a first-of-its-kind genomics initiative called In Our DNA SC.
  • The genetic reports will allow patients and their health providers to develop precision health care plans to proactively mitigate the conditions and take a more preventive approach to patient care.
  • This collaboration will help drive preventive, precision health care for South Carolinians."

Illumina Ventures Closes $325 Million Fund

Monday, September 20, 2021 - 1:00pm

Illumina Ventures, an independently-managed, healthcare-focused venture firm, announced today the closing of its second investment fund with total commitments of $325 million, bringing its total capital under management to $560 million.

Key Points: 
  • Illumina Ventures, an independently-managed, healthcare-focused venture firm, announced today the closing of its second investment fund with total commitments of $325 million, bringing its total capital under management to $560 million.
  • "Our investment in Illumina Ventures furthers our objective of supporting innovation in the genomics ecosystem," said Francis DeSouza, CEO of Illumina.
  • Paul Saunders, Senior Investment Director at the Ireland Strategic Investment Fund (ISIF), said: "We are delighted to be supporting Illumina Ventures' second fund.
  • Illumina Ventures is an independently managed, healthcare-focused venture firm in a strategic partnership with Illumina, with the vision to unlock the power of the genome.

Complete AAV Production System Enables Scalable Gene Therapy Workflows

Monday, September 20, 2021 - 1:05pm

CARLSBAD, Calif., Sept. 20, 2021 /PRNewswire/ --Addressing the need to make adeno-associated virus (AAV) production more efficient and scalable, Thermo Fisher Scientific has launched the integrated Gibco AAV-MAX Helper Free AAV Production System*, a complete, optimized solution that simplifies the AAV vector production workflow.

Key Points: 
  • CARLSBAD, Calif., Sept. 20, 2021 /PRNewswire/ --Addressing the need to make adeno-associated virus (AAV) production more efficient and scalable, Thermo Fisher Scientific has launched the integrated Gibco AAV-MAX Helper Free AAV Production System*, a complete, optimized solution that simplifies the AAV vector production workflow.
  • AAV is crucial to the field of gene therapy; more than 1,300 unique gene therapy products are currently under development, and nearly half are reliant on AAV.The ability to scale production is critical to bringing down costs and accelerating the process from research to commercialization.
  • "The new AAV production system is part of our end-to-end workflow solutions designed to meet growing demand for cost-effective, scalable viral vector production.
  • To learn more about the Gibco AAV-MAX Helper Free AAV Production System, please visit www.thermofisher.com/aavmax .

Aviceda Therapeutics Announces Additional World-Class Members to its Scientific Advisory Board

Monday, September 20, 2021 - 1:00pm

Aviceda Therapeutics, an IND-stage, pre-clinical biotech company focused on developing the next generation of immuno-modulators by harnessing the power of glycobiology to manipulate the innate immune system and chronic, non-resolving inflammation, is announcing additional members of its Scientific Advisory Board who will help shape ongoing research and development efforts.

Key Points: 
  • Aviceda Therapeutics, an IND-stage, pre-clinical biotech company focused on developing the next generation of immuno-modulators by harnessing the power of glycobiology to manipulate the innate immune system and chronic, non-resolving inflammation, is announcing additional members of its Scientific Advisory Board who will help shape ongoing research and development efforts.
  • The new additional Aviceda Scientific Advisory Board members includes:
    Aviceda is honored and privileged to add new world-class scientists and renowned researchers to join our efforts in developing the next generation of glyco-immune therapeutics for the treatment of immune-dysfunction conditions, said Mohamed A. Genead, MD, Co-Founder & President of Aviceda Therapeutics.
  • She published more than 280 scientific papers in well recognized journals (Cell, Nature, Nature Immunology, PNAS, and JEM) and supervised 29 PhD students.
  • The Aviceda team is already building on the foundational work in the emerging field of glycobiology to develop potential therapeutics and interventional strategies.

Cyteir Therapeutics Selected to Join Russell 2000® Index

Monday, September 20, 2021 - 12:30pm

Cyteir Therapeutics, Inc. (Cyteir) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer was added as a member of the U.S. small-cap Russell 2000 Index, effective after the US market opens on September 20, as part of the 2021 Russell indexes reconstitution.

Key Points: 
  • Cyteir Therapeutics, Inc. (Cyteir) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer was added as a member of the U.S. small-cap Russell 2000 Index, effective after the US market opens on September 20, as part of the 2021 Russell indexes reconstitution.
  • Membership in the Russell 2000 Index, which remains in place for one year, is based on membership in the broad-market Russell 3000 Index.
  • "We are pleased to be included in the Russell 2000 Index following the successful close of our June IPO.
  • For more information on the Russell 2000 Index and the Russell indexes reconstitution, go to the Russell Reconstitution section on the FTSE Russell website .

Matinas BioPharma Announces Accomplished Biotechnology Executive and Drug Developer Kathryn Penkus Corzo as Nominee to the Board of Directors

Monday, September 20, 2021 - 12:00pm

BEDMINSTER, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platform delivery technology, today announced the nomination of Kathryn Penkus Corzo to stand for election to the Company’s Board of Directors at its 2021 Annual Meeting of Stockholders, scheduled for November 1, 2021.

Key Points: 
  • We are thrilled to nominate Kathryn to our Board of Directors, stated Herbert Conrad, Chairman of the Matinas BioPharma Board of Directors, and Chair of the Nominating and Governance Committee.
  • Ms. Corzo commented, I am honored to have been nominated to join the Matinas Board of Directors at such an exciting time for the Company.
  • On behalf of the Board of Directors and Matinas, I would like to thank Pat LePore for his service to the Company.
  • Kathryn Corzo is a biotechnology executive who has served in senior leadership roles for several leading biotechnology and pharmaceutical companies.